Compare Hershey Co (HSY) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Eli Lilly And Co — how do they compare? Hershey Co trades at $162.36 (market cap $32.66B), while Eli Lilly And Co trades at $1,177 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 31.8× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.57%). Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Eli Lilly And Co for 93 Days on average.
| HSY | LLY | |
|---|---|---|
Market Cap | $32.66B | $1.04T |
Volume | 1,578,237 | 3,064,878 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $1.28K |
52-Week Low | $157.61 | $799.57 |
Typical Hold Time | 135 Days | 93 Days |
Enterprise Value | $37.79B | $1.09T |
Dividend Yield | 3.57% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $161.88, up 0.96% with a bearish technical outlook. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though Q3 2026 earnings are pending. Recent news highlights brand investments and dividend resumption after a near 2-year freeze. Valuation metrics include P/E of 22.2 and P/S of 2.72, with analyst consensus price target at $204.62 representing 26% upside potential.
HSY presents a mixed investment case with strong fundamentals offset by near-term headwinds. The opportunity lies in consistent dividend growth potential and market leadership, while risks include commodity cost pressures and competitive challenges. Analyst sentiment leans cautious with 66% hold ratings, suggesting patience for earnings catalysts and margin stabilization.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
